Abstract Number: 0927 • ACR Convergence 2020
Care Gap in Patients with Systemic Sclerosis with CXR Findings Suggestive of Fibrosis
Background/Purpose: Lung involvement, including interstitial lung disease (ILD), is the leading cause of death in patients with systemic sclerosis (SSc). High resolution CT (HRCT) is…Abstract Number: 1078 • ACR Convergence 2020
Highly Reactive anti-Jo1 Autoantibodies to Distinct HisRS Variants and Domains Associate with Lung and Joint Involvement in Patients with Myositis
Background/Purpose: To address the reactivity and affinity against histidyl-transfer RNA synthetase (HisRS) autoantigen of anti-Jo1 autoantibodies from serum and bronchoalveolar lavage fluid (BALF) and associations…Abstract Number: 1383 • ACR Convergence 2020
Tocilizumab Shows Potential in Preserving Lung Function in Systemic Sclerosis with Positive anti-topoisomerase-1 (Scl-70): A Single Centre Cohort Study
Background/Purpose: Recent Phase II (faSScinate) and Phase III (focuSSced) clinical trials of tocilizumab versus placebo in early dcSSc highlighted the potential impact of tocilizumab on…Abstract Number: 0929 • ACR Convergence 2020
The Effect of Mycophenolate Mofetil on Pulmonary Function Tests in Patients with Systemic Sclerosis-associated Interstitial Lung Disease, and the Difference Between the African Americans versus Non-African Americans
Background/Purpose: Scleroderma-related interstitial lung disease (SSc-ILD) is a pulmonary fibrosing disorder characterized by systemic inflammation and progressive scarring of the lungs that leads to respiratory…Abstract Number: 1082 • ACR Convergence 2020
The Presence of Anti-Jo1, anti-PL7, And/or anti-MDA5 Antibodies in Idiopathic Inflammatory Myopathy Confers an Increased Risk of a Significant Restrictive Pulmonary Defect
Background/Purpose: A subset of patients with idiopathic inflammatory myopathy develop significant restrictive lung disease, although risk factors for this are poorly defined. Autoantibodies may be…Abstract Number: 1431 • ACR Convergence 2020
Interstitial Lung Disease in Patients with ANCA Associated Vasculitis – a Prospective Single Centre Study
Background/Purpose: Recently, an association between anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) and interstitial lung disease (ILD) has been uncovered. We aimed to determine the rate…Abstract Number: 874 • 2019 ACR/ARP Annual Meeting
Comparative Analysis Between ANCA-associated Interstitial Lung Disease and Interstitial Pneumonitis with Autoimmune Features
Background/Purpose: Anti-neutrophil cytoplasmic antibodies (ANCA) have been identified in patients who have pneumonia without a diagnosis of ANCA-associated vasculitis (AAV). These patients are presently categorized…Abstract Number: 1834 • 2019 ACR/ARP Annual Meeting
Serum Interferon Chemokine Score Predicts Better Response to Immunosuppression in Systemic Sclerosis Related Interstitial Lung Disease
Background/Purpose: Response to immunosuppression is highly variable in systemic sclerosis (SSc) related interstitial lung disease (ILD), and there are no widely accepted clinical or biological…Abstract Number: 2610 • 2019 ACR/ARP Annual Meeting
Relationship Between Parenchymal and Vascular Features in Systemic Sclerosis-Interstitial Lung Disease: Results from Quantitative Analysis of Chest Computed Tomography
Background/Purpose: Interstitial lung disease (ILD) and pulmonary arterial hypertension negatively impact on Systemic sclerosis (SSc) prognosis. Chest computed tomography (CT) is the gold standard in…Abstract Number: 962 • 2019 ACR/ARP Annual Meeting
The Presence of Circulating CD19+CD21lo cells Predicts the Presence of Interstitial Lung Disease in Patients with Systemic Sclerosis
Background/Purpose: Systemic sclerosis (SSc) is a severe systemic disease characterized by fibrosis of the skin and visceral organs. While protein biomarkers of lung damage, e.g.…Abstract Number: 2066 • 2019 ACR/ARP Annual Meeting
Clinical, Serologic and Morphologic Features of Interstitial Pneumonia with Autoimmune Features (IPAF): A Single Center Experience
Background/Purpose: Interstitial lung disease (ILD) encompasses a group of disorders that are classified together based on similar clinical, radiographic and pathologic findings. ILD is highly…Abstract Number: 2616 • 2019 ACR/ARP Annual Meeting
Forced Vital Capacity Trajectories for Systemic Sclerosis-associated Interstitial Lung Disease—Analysis from the University of Michigan Scleroderma Cohort
Background/Purpose: Interstitial Lung Disease (ILD) is the leading cause of morbidity and mortality in systemic sclerosis (SSc) patients. Forced Vital Capacity (FVC, recorded as %…Abstract Number: 1274 • 2019 ACR/ARP Annual Meeting
New Aspects of Clinical and Immunological Characteristics in Patients with Anti-KS Antibody
Background/Purpose: Anti-KS antibody, an anti-aminoacyl tRNA synthetase (ARS) antibody, is found mainly in patients with interstitial lung disease (ILD) accompanied by polymyositis/dermatomyositis (PM/DM). Although anti-KS…Abstract Number: 2135 • 2019 ACR/ARP Annual Meeting
Therapeutic Strategies and Survival in Patients with Interstitial Pneumonia with Autoimmune Features
Background/Purpose: Recently the term “interstitial pneumonia with autoimmune features” (IPAF) has been proposed to identify patients with interstitial lung disease and autoimmune characteristics, not fulfilling…Abstract Number: 1286 • 2019 ACR/ARP Annual Meeting
Patients with Anti-tRNA Synthetase Syndrome Are More Likely to Present to Pulmonary Clinic and Have a Higher Prevalence and Severity of Lung Disease Than Patients with Other Types of Myositis or Systemic Sclerosis
Background/Purpose: Interstitial lung disease (ILD) is a significant cause of morbidity and mortality in idiopathic inflammatory myopathies (IIM) as well as systemic sclerosis (SSc). The…
- « Previous Page
- 1
- …
- 27
- 28
- 29
- 30
- 31
- …
- 39
- Next Page »